GetTopicDetailResponse(id=60f111932497, topicName=DP303c, introduction=, content=抗體偶聯(lián)藥物 DP303c, image=null, comments=0, allHits=476, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Fri Sep 20 18:17:22 CST 2024, time=2024-09-20, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=495968, tagList=[TagDto(tagId=495968, tagName=DP303c)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2226804, encodeId=4e37222680433, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗體偶聯(lián)藥物#</a> <a href='/topic/show?id=60f111932497' target=_blank style='color:#2F92EE;'>#DP303c#</a>, objectTitle=靶向HER2的抗體偶聯(lián)藥DP303c臨床治療效果首次公布，近70%的實(shí)體瘤病情得以控制！, objectType=article, longId=842790, objectId=d753842e90f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240719/1721369354422_8538692.jpg, objectUrl=/article/show_article.do?id=d753842e90f3, replyNumber=0, likeNumber=89, createdTime=2024-09-20, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d753842e90f3, moduleTitle=靶向HER2的抗體偶聯(lián)藥DP303c臨床治療效果首次公布，近70%的實(shí)體瘤病情得以控制！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d753842e90f3)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-09-20發(fā)表于上海
